Proceedings of the Korean Society of Toxicology Conference (한국독성학회:학술대회논문집)
- 2002.11b
- /
- Pages.199-200
- /
- 2002
Investigation of genomic integration of GX-12, a new anti-HIV DNA vaccine, into host cellular DNA following intramuscular injection in rats
- Kang, Kyung-Koo (Research Laboratories, Dong-A Pharm. Co. Ltd.) ;
- Park, Min-Seul (Research Laboratories, Dong-A Pharm. Co. Ltd.) ;
- Ahn, Jun-Kook (Research Laboratories, Dong-A Pharm. Co. Ltd.) ;
- Baik, Dae-Hyun (Research Laboratories, Dong-A Pharm. Co. Ltd.) ;
- Lee, Dong-Sup (Research Laboratories, Dong-A Pharm. Co. Ltd.) ;
- Park, Jae-Hun (Research Laboratories, Dong-A Pharm. Co. Ltd.) ;
-
Ahn, Byoung-Ok
(Research Laboratories, Dong-A Pharm. Co. Ltd.)
;
- Kim, Won-Bae (Research Laboratories, Dong-A Pharm. Co. Ltd.)
- Published : 2002.11.01
Abstract
GX-12 is a naked DNA vaccine developed by research team of Dong-A Pharmaceutical Company, Green Cross Company and Genexine for the treatment of HIV infection. It consists of four separate plasmids (pGX10-GE HX, pGX10-dpol JR, pGX10-VN/TV JR, pGX10-hIL-12m), which were constructed by inserting the HIV-1 gag-env, pol, regulatory genes and a human IL-12 mutant gene into pGX10 plasmid vectors.(omitted)